Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Cash from Operations of 36882000.0 for Q1 2026, up 7.39% year-over-year from 34344777.81 in Q1 2025, and down 32.18% quarter-over-quarter from 27903000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Cash from Operations history runs 6 years deep, the most recent figure standing at 36882000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 7.39% year-over-year to 36882000.0; the TTM figure through Mar 2026 stood at 120401000.0 (up 41.83% YoY), while the FY2025 annual figure was 123343000.0, up 26.43% from the prior year.
- Cash from Operations for Q1 2026 stood at 36882000.0, down from 27903000.0 in the prior quarter.
- The five-year high for Cash from Operations was 13551000.0 in Q4 2023, with the low at 66580000.0 in Q2 2024.
- The 5-year median for Cash from Operations is 36882000.0 (2026), against an average of 29166117.65.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations jumped 127.27% in 2023, then plunged 8043.97% in 2025.
- Amylyx Pharmaceuticals' Cash from Operations stood at 49697000.0 in 2022, then soared by 127.27% to 13551000.0 in 2023, then tumbled by 535.45% to 59008000.0 in 2024, then soared by 52.71% to 27903000.0 in 2025, then sank by 32.18% to 36882000.0 in 2026.
- Business Quant data shows AMLX's Cash from Operations at 36882000.0 in Q1 2026, 27903000.0 in Q4 2025, and 30368000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.41 Bn | 4.41 Bn | - | -31.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.42 Mn |
| Jun 30, 2026 | -31.42 Mn |
| Mar 31, 2026 | -36.88 Mn |
| Mar 31, 2026 | -36.88 Mn |
| Dec 31, 2025 | -27.90 Mn |
| Dec 31, 2025 | -27.90 Mn |
| Sep 30, 2025 | -30.37 Mn |
| Sep 30, 2025 | -30.37 Mn |
| Jun 30, 2025 | -25.25 Mn |
| Jun 30, 2025 | -25.25 Mn |
| Mar 31, 2025 | -39.82 Mn |
| Mar 31, 2025 | -39.82 Mn |
| Dec 31, 2024 | -59.01 Mn |
| Dec 31, 2024 | -59.01 Mn |
| Sep 30, 2024 | -41.57 Mn |
| Sep 30, 2024 | -41.57 Mn |
| Jun 30, 2024 | -66.58 Mn |
| Jun 30, 2024 | -66.58 Mn |
| Mar 31, 2024 | -489,000.00 |
| Mar 31, 2024 | -489,000.00 |